Novel CD for Niemann-Pick C

About CycloLab

CycloLab is a well-established, private Hungarian biotech with a 30-year legacy in cyclodextrin technology. It has a dual business model combining the sale of a broad portfolio of cyclodextrin derivatives with contract research and development services for various industries. The company is advancing an internal pipeline, including a novel cyclodextrin-based API for Niemann-Pick C disease and a reformulation program for lonafarnib, while seeking partners for clinical development. Its core strength lies in its extensive library of cyclodextrin compounds and GMP manufacturing capabilities.

Therapeutic Areas